

FOI 1781

19/07/23

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. Does your trust treat myeloproliferative neoplasms? If not, which other trust do you refer these patients to?

Yes

Q2. Please provide the total number of patients treated in the last 6 months for:

- **Polycythaemia Vera (ICD10 code D45)**
- **Myelofibrosis (ICD10 code D47.4)**
- **Myelofibrosis (ICD10 code D47.4) patients aged 65 and older**

Please see attached document for response.

Q3. How many patients were treated in the past 6 months (for any disease) with:

- **Ruxolitinib 12**
- **Fedratinib 0**

Q4. Of the patients treated in the past 6 months with Ruxolitinib, how many patients had a diagnosis for:

- **Polycythaemia Vera (ICD10 code D45) 5**
- **Myelofibrosis (ICD10 code D47.4) 7**

Q5. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

Please see attached document for response.

- **Of these patients, how many were treated in the past 6 months with Hydroxycarbamide?** <5.

Where there is low numbers we have provided <5 as releasing the exact number has the potential to lead to the identification of an individual (s). Therefore the Trust has applied Section 40 (2) (third party information) of the Freedom of Information Act 2000 to exempt any numbers less than 5.

- **Of these patients, how many were treated in the past 6 months with Interferon therapy?** 0
- **Of these patients, how many have received no active treatment in the past 6 months?** Information not held by pharmacy

Q6. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.

No

Email: foi.team@southerntrust.hscni.net